Alamar Biosciences, ordinary share
ALMR, US0109111056
CBONDSウォッチリストで投資を発見、保存、追跡
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
最も包括的なデータベースを探索
1 000 000
債券
100 000
株
175 910
ETF&投資信託
100 000
インデックス
最も効率的な方法でポートフォリオを追跡
|
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at
...
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
|